NO20074414L - 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft - Google Patents

1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft

Info

Publication number
NO20074414L
NO20074414L NO20074414A NO20074414A NO20074414L NO 20074414 L NO20074414 L NO 20074414L NO 20074414 A NO20074414 A NO 20074414A NO 20074414 A NO20074414 A NO 20074414A NO 20074414 L NO20074414 L NO 20074414L
Authority
NO
Norway
Prior art keywords
carboxamides
cancer
fak
kdr
pyrrole
Prior art date
Application number
NO20074414A
Other languages
English (en)
Norwegian (no)
Inventor
Baptiste Ronan
Michel Tabart
Fabrice Viviani
Youssef El-Ahmad
Eric Bacque
Frank Halley
Catherine Souaille
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20074414L publication Critical patent/NO20074414L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20074414A 2005-02-03 2007-08-29 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft NO20074414L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501092A FR2881426B1 (fr) 2005-02-03 2005-02-03 Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
PCT/FR2006/000220 WO2006082309A1 (fr) 2005-02-03 2006-02-01 l-H-PYROLE-2-CARBOXAMIDES ET IMIDAZOLE-5-CARBOXAMIDES ET LEUR UTILISATION EN TANT MODULATEURS DES KINASES FAK, KDR ET TIE2 POUR TRAITER LE CANCER

Publications (1)

Publication Number Publication Date
NO20074414L true NO20074414L (no) 2007-11-05

Family

ID=34954950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074414A NO20074414L (no) 2005-02-03 2007-08-29 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft

Country Status (20)

Country Link
US (1) US7560571B2 (pt)
EP (1) EP1856043B1 (pt)
JP (1) JP2008528661A (pt)
KR (1) KR20070103420A (pt)
CN (1) CN101133023A (pt)
AR (1) AR053540A1 (pt)
AT (1) ATE512133T1 (pt)
AU (1) AU2006210343A1 (pt)
BR (1) BRPI0606761A2 (pt)
CA (1) CA2595987A1 (pt)
EA (1) EA012267B1 (pt)
FR (1) FR2881426B1 (pt)
IL (1) IL184710A0 (pt)
MA (1) MA29264B1 (pt)
MX (1) MX2007009442A (pt)
NO (1) NO20074414L (pt)
TW (1) TW200640857A (pt)
UY (1) UY29361A1 (pt)
WO (1) WO2006082309A1 (pt)
ZA (1) ZA200706338B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
US7589214B2 (en) 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
HUE031580T2 (en) 2008-08-15 2017-07-28 Nivalis Therapeutics Inc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP2315590B1 (en) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Pyrrole inhibitors of s-nitrosoglutathione reductase
CN102775354A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 一种合成4-芳基-5-羧酸咪唑及其酯的工艺方法
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
PE20181074A1 (es) 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN119528787A (zh) * 2023-08-31 2025-02-28 上海柏狮生物科技有限公司 以异腈和Michael受体制备一系列沃诺拉赞中间体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
EP1436265A4 (en) * 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
EP1633709A1 (en) * 2003-04-30 2006-03-15 Pfizer Products Inc. Anti-diabetic agents
DE10354060A1 (de) * 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
ZA200706338B (en) 2008-11-26
KR20070103420A (ko) 2007-10-23
BRPI0606761A2 (pt) 2009-07-14
AR053540A1 (es) 2007-05-09
WO2006082309A1 (fr) 2006-08-10
EP1856043A1 (fr) 2007-11-21
FR2881426A1 (fr) 2006-08-04
UY29361A1 (es) 2006-08-31
AU2006210343A1 (en) 2006-08-10
IL184710A0 (en) 2007-12-03
EA012267B1 (ru) 2009-08-28
ATE512133T1 (de) 2011-06-15
TW200640857A (en) 2006-12-01
US7560571B2 (en) 2009-07-14
US20080045542A1 (en) 2008-02-21
CA2595987A1 (fr) 2006-08-10
MX2007009442A (es) 2008-03-10
CN101133023A (zh) 2008-02-27
MA29264B1 (fr) 2008-02-01
FR2881426B1 (fr) 2007-03-30
JP2008528661A (ja) 2008-07-31
EA200701648A1 (ru) 2008-02-28
EP1856043B1 (fr) 2011-06-08

Similar Documents

Publication Publication Date Title
UA107783C2 (en) Isoindoline compounds for use in treating cancer
TW200714604A (en) Substituted heterocycles and the uses thereof
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
BRPI0915084B8 (pt) composto, e, composição farmacêutica
NO20090295L (no) Substituerte heteroarylderivater
EA201170772A1 (ru) Органические соединения
SE0301700D0 (sv) Novel compounds
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
NO20084852L (no) MGLUR5 modulatorer V
SE0401762D0 (sv) Novel compounds
NO20084352L (no) Dimerer av artemisininderivater, fremstilling derav og terapeutisk anvendelse derav
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA201001639A1 (ru) Композиции и способы их получения и применения
MY152018A (en) Indole derivatives as anticancer agents
TW200738659A (en) Novel compounds
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application